- Fourth quarter 2025 revenue up 75% compared to the fourth quarter 2024
- Fourth quarter 2025 gross profit increased 78% compared to the fourth quarter 2025
- Fourth quarter same-store sales up 6% and same-store prescription sales up 3.8 %, supplementary financial measures, both compared to fourth quarter 2025
SASKATOON, Saskatchewan, April 29, 2026 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation“) (TSXV:PCRX) a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy ownership, today reported its financial results for fourth quarter and year ended December 31, 2025.
“Our financial results reflect our steady progress in scaling the business through disciplined M&A, the successful integration of recently acquired stores, and the operational excellence of our pharmacies,” said Alan Simpson, Executive Chairman of PharmaCorp. “Looking ahead, the ongoing interest from independent pharmacy owners considering their succession options continues to fuel the expansion of our unique pipeline of M&A opportunities across Canada. We remain confident in our ability to further scale our business through accretive transactions in fiscal 2026 as we work towards building a national platform.”
Fourth Quarter 2025 and Fiscal Year 2025 Financial Highlights
- Fourth quarter 2025 revenue of $7.7 million compared to $4.4 million in the fourth quarter of 2024, representing an increase of 75 %. Fiscal year 2025 revenue of $20.9 million compared to $5.8 million in 2024.
- Fourth quarter 2025 gross profit of $2.9 million compared to $1.7 million in the fourth quarter of 2024 with margins of 39% and 38% respectively. Fiscal year 2025 gross profit of $8.3 million compared to $2.2 million in 2024.
- Fiscal year 2025 Adjusted EBITDA, a Non-IFRS Financial Measure, of $3.5 million compared to $0.85 million in 2024.
- Revenues, gross profit and Adjusted EBITDA were higher year-over-year for the quarterly and annual periods due to increases in prescription volumes and front-of-store sales and owning more pharmacies in the fourth quarter of 2025 and fiscal 2025 versus the prior-year periods.
- Fourth quarter same-store sales, a supplementary financial measure, increased 6% compared to the fourth quarter of 2024, reflecting continued organic growth across PharmaCorp’s pharmacy network.
- Fourth quarter same-store prescription sales continued to grow, with total script count rising 3.8% compared to the fourth quarter of 2024, demonstrating sustained patient engagement and activity across the network.
- Fourth quarter 2025 net loss of $0.64 million compared to $0.72 million in the fourth quarter of 2024, representing a decrease of 11%. Fiscal year 2025 net loss of $1.4 million compared to $1.1 million in 2024. Net loss was higher year-over-year for the annual periods due to expenses related to the Corporation’s credit agreement and charter purchase.
- As of December 31, 2025, the Corporation had cash of $25.9 million compared to $12.9 million at the end of 2024.
Operational Highlights
- On October 2, 2025, PharmaCorp announced the acquisition of two pharmacies located in Western Canada, one of which includes the associated land and building, and announced that it purchased a pharmacy located in Eastern Canada. The three pharmacies are performing as anticipated, and the integration of the two Western Canada pharmacies is going as planned.
- On November 12, 2025, PharmaCorp announced the closing a bought deal public offering for gross proceeds of approximately $23 million.
- On December 1, 2025, PharmaCorp announced the appointment of Paul Dale as President and Chief Operating Officer.
Further Information
For comprehensive disclosure of PharmaCorp’s financial performance for the fourth quarter and year ended December 31, 2025, and its financial position as at such date, please see PharmaCorp’s Consolidated Annual Financial Statements and related Management’s Discussion and Analysis …